Granon (Acetylcysteine)

Granon is indicated for mucolytic therapy in a variety of respiratory conditions where thick or tenacious secretions impair ventilation.

• Chronic bronchitis associated with productive cough.
• Chronic obstructive pulmonary disease (COPD) exacerbations.
• Asthma with mucus hypersecretion.
• Acute upper respiratory tract infections that produce viscous sputum.
• Post‑operative or post‑traumatic situations where airway clearance is desired.

The safety profile of Granon reflects the typical effects observed with oral acetylcysteine, most of which are mild and transient. These effects are generally dose‑related and resolve after discontinuation.

Common

• Nausea or mild gastrointestinal upset, often occurring shortly after the dose.
• Vomiting, which may be transient and does not usually require medical intervention.
• Unpleasant metallic or salty taste in the mouth that typically diminishes with continued use.

Serious

• Allergic skin reactions such as rash, urticaria, or itching that may require antihistamine therapy.
• Bronchospasm or worsening of respiratory symptoms, particularly in individuals with asthma.
• Anaphylactic reaction, a rare but severe systemic hypersensitivity that necessitates immediate emergency care.

When using Granon, certain precautions help ensure safe and effective therapy, especially in populations with underlying health conditions.

• Assess for known hypersensitivity to acetylcysteine or any excipients before initiating therapy.
• Use caution in patients with active asthma or a history of bronchospasm, as inhaled irritation may occur.
• Monitor liver function during prolonged or high‑dose use, given the role of acetylcysteine in glutathione metabolism.
• Adjust dosage or seek medical advice for individuals with renal impairment, as excretion may be affected.
• Pregnant or breastfeeding women should consult a healthcare professional before use, due to limited safety data.
• Avoid concurrent use with other mucolytic agents unless directed by a clinician to prevent excessive thinning of secretions.

Granon may interact with certain medications, affecting either its mucolytic action or the pharmacodynamics of the co‑administered drug.

Avoid

• Concurrent use with nitroglycerin or other vasodilators, as acetylcysteine can potentiate hypotensive effects.
• Simultaneous administration of activated charcoal, which may reduce acetylcysteine absorption.

Use with caution

• Anticoagulants (e.g., warfarin) – monitor coagulation parameters because acetylcysteine may alter platelet function.
• Antibiotics that rely on thick mucus for localized effect; mucolysis may change drug distribution.
• Other mucolytic or expectorant products – combined use may increase risk of gastrointestinal irritation.